Rights and permissions
About this article
Cite this article
Infliximab for IBD: clinical benefits at acceptable costs. Pharmacoecon. Outcomes News 618, 5 (2010). https://doi.org/10.2165/00151234-201006180-00012
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201006180-00012